Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892002 · ClinicalTrials.gov registry record
Description of Patients With Type 1 Diabetes Treated With Teplizumab
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 110
- Enrollment target
NCT06892002: Completed study, sponsored by Sanofi.
NCT06892002 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892002 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms; most patients with Stage 3 T1D meet standard diagnostic criteria for diabetes and require insulin treatment. Teplizumab has been shown to delay progression to Stage 3 in participants at Stage 2 in a Phase 2 clinical trial, leading to subsequent approval in the United States of America (USA). Patients outside of the USA are able to receive the treatment through Pre-Registration Import Licenses and Managed Access Programs. The current study will collect data on the use of teplizumab in routine care, to better understand which patients received teplizumab and how these patients were managed after they received the treatment.
Primary Outcome
Age, sex at birth, race (for US participants only), ethnicity (for US participants only), height, weight, Body mass index (BMI)
Interventions
- DRUG Teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2025-08-05 |
What the finished NCT06892002 record still lists
NCT06892002 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Teplizumab is the first listed.
NCT06892002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06892002 about?
NCT06892002 is a clinical study titled "Description of Patients With Type 1 Diabetes Treated With Teplizumab". Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia ...
What is the current status of trial NCT06892002?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2025-02-11. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT06892002?
The interventions under investigation include: Teplizumab (DRUG).
Who is sponsoring clinical trial NCT06892002?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI